Advanced searches left 3/3

Metastatic Neuroendocrine Tumors - DOAJ

Summarized by Plex Scholar
Last Updated: 20 May 2022

* If you want to update the article please login/register

Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis

This retrospective review and divided into three groups was chosen from a pool of patients with low-grade FDG uptake at baseline, SUVmax 5–10, and Group 3 consisting of patients with low-grade FDG uptake at baseline, defined as SUVmax > 10 ; and Group 1 contained patients with low-grade metastatic NET; and Group 2 consisted of patients with low-grade FDG uptake at baseline, defined as SUVmax > 10 ; and Group 2 was composed of patients with defining SUVmax NET These patients also had improved PFS and OS, as well as a reduced hazard ratio compared to patients in Group 3. Patients of low-to-moderate baseline tumor FDG metabolism exhibited a positive symptomatic response, provided with improved biochemical and anatomical disease control, and were associated with increased PFS and OS in comparison to those with high-grade baseline tumor FDG metabolism.

Source link: https://doi.org/10.4103/wjnm.WJNM_62_18


Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Adults with carcinoid tumors of the digestive tract were randomly selected to receive pasireotide LAR or octreotide LAR every 28 days, or octreotide LAR. Based on the frequency of bowel movements and flushing episodes, the primary outcome was symptom control. The data monitoring committee at the time of a proposed interim review recommended that the research be delayed due to a low chance of showing superiority of pasireotide over octreotide for symptom control. Tumor control rate at month 6 was 67% with pasireotide and 46. 2% with octreotide, and 42. 2% with octreotide was 67%. Months with pasireotide compared to 6. 8 months with octreotide, according to Median PFS. Patients with carcinoid symptoms refractory to available somatostatin analogues, and similar numbers of patients receiving pasireotide LAR or octreotide LAR achieved symptom control at month 6. At month 6, Pasireotide LAR showed a rise in tumor control rates, but it was not statistically significant and was linked to a longer PFS than octreotide LAR.

Source link: https://doaj.org/article/6b97e84180fa43e6ba5765a7f80687da


68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan

Background/purpose: The aim was to investigate the diagnostic accuracy of 68Ga-DOTATOC and 18F-FDG PET/CT to determine the primary foci in Taiwanese patients with clinically suspected neuroendocrine tumors and the NET of a mystery primary site. Patients with medically impaired NET and NET of unidentified primary site were eligible. Results: We were able to identify the primary tumor in 17 participants out of 36 patients in the study. In 12 of the 36 study participants, treatment changes as a result of 68Ga-DOTATOC PET/CT findings.

Source link: https://doi.org/10.1016/j.jfma.2017.07.007


Hepatic Arterial Embolization for the Treatment of Metastatic Neuroendocrine Tumors

Neuroendocrine tumors have a high tendency for metastasizing to the liver and can cause severe debilitating symptoms adversely impacting quality of life. Although surgery is the preferred treatment of choice, many liver metastases are inoperable at present, and at surgery, some liver metastases are inoperable. The arterial supply of NET metastases is used by Hepatic arterial embolization procedures. Patients treated with hepatic arterial embolization have longer survival rates and 5-year survival rates of nearly 30%, with 5-year survival rates exceeding 60%. Despite not being curative, hepatic arterial embolization should be used in the treatment of NETs with liver metastases.

Source link: https://doi.org/10.1155/2012/471203


Metastatic neuroendocrine tumors mimicking as primary ocular disease

To describe two cases of metastatic neuroendocrine tumors masquerading as primary ocular disease, we must refer to two cases. Observations: Case 1 is a 38-year-old man who was described as having subacute diplopia and a fluctuating ptosis that is suggestive of myasthenia gravis. Case 2 is a 21-year-old man who had blurry vision and was discovered to have a pigmented ciliary body mass and retinal detachment that suggestive of uveal melanoma.

Source link: https://doi.org/10.1016/j.ajoc.2022.101425

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions